Kazia Therapeutics (KZIA) Cash from Financing Activities (2016)

Kazia Therapeutics (KZIA) posted Cash from Financing Activities of -$13249.3 for Q4 2016.

Kazia Therapeutics (KZIA) Cash from Financing Activities (2016) Analysis & Trends

Kazia Therapeutics' Cash from Financing Activities history runs 1 years deep, the most recent figure standing at -$13249.3 for Q4 2016.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 30.14 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 68.63 Mn
4 NuCana 279.75 Bn 279.75 Bn - 9,311.16
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -538.80 Mn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -802.20 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - 238.74 Mn
10 Kazia Therapeutics 4.11 Mn 4.11 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2016 -13,249.30
Dec 31, 2016 -13,249.30